ArticlePloS one2026
Pan-cancer profiles of mesothelin (MSLN) unveil diagnostic potential and therapeutic targetability of pancreatic adenocarcinoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesothelin (MSLN) is a cell surface glycoprotein that is often over-expressed in various malignancies of humans and has been suggested as a potential therapeutic and diagnostic target. However, its expression profile, clinical implications and drug-targeting potential are not fully understood and needs to be investigated across various cancer types.
objectivesThe goal of this study was to systematically characterize the MSLN expression pattern, its prognostic value and functionality in different types of cancers, particularly in pancreatic adenocarcinoma (PAAD), as well as to identify viable therapeutic target opportunities.
methodsTranscriptomic and clinical datasets from TCGA and GEO were used to evaluate the expression of the MSLN gene, diagnostic value, and its prognostic significance. To study the genomic alterations and functional pathways of MSLN, mutation, GO, and KEGG analyses were used. Drug sensitivity correlations were performed with GDSC and CTRP datasets. Structure-based drug discovery involved molecular docking (AutoDock Vina and Maestro Glide), 100 ns molecular dynamics simulations, and MMPBSA binding free energy analysis, followed by drug-likeness and toxicity assessment using SwissADME and ProTox-III.
resultsMSLN was found to be over expressed in several cancers, including PAAD, ovarian and mesothelioma, and this was confirmed in the independent GEO datasets. The analysis of ROC curves showed high accuracy for PAAD and stomach adenocarcinoma and moderate to low accuracy for the other cancers. Both survival and Cox regression analyses showed that MSLN was a cancer-type-specific prognostic factor. Analysis of mutations showed low frequencies of genetic changes, suggesting that the mechanism of dysregulation may be transcriptional or epigenetic. Enrichment analysis highlighted immune-related and tumor-microenvironment signaling pathways associated with MSLN. Drug sensitivity analysis suggested association of MSLN expression with response to targeted and selected chemotherapeutic drugs. Molecular docking revealed Withaferin A as the most potent protein binding compound with MSLN with stable protein-ligand interaction as evidenced by molecular dynamics simulations and binding energy analysis.
conclusionMSLN is a diagnosis and prognosis biomarker that is context dependent and has application in selected cancers, especially pancreatic adenocarcinoma. While Withaferin A shows promising in silico binding and stability against MSLN, predicted toxicity and pharmacokinetic limitations suggest the need for further optimization and experimental validation before therapeutic application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.